Lung Cancer Dispatch
Follow
Find tag "angiogenesis"
3.7K views | +1 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Docetaxel Plus Ramucirumab Improves Outcomes in Advanced NSCLC

Docetaxel Plus Ramucirumab Improves Outcomes in Advanced NSCLC | Lung Cancer Dispatch | Scoop.it

"The addition of ramucirumab to docetaxel improved outcomes over placebo with docetaxel as a second-line treatment of patients with advanced non-small-cell lung cancer (NSCLC), according to results of the REVEL trial presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.


“ 'Despite advancements in genomics and identification of predictive biomarkers such as EGFR mutations or ALK rearrangement, there is still no… targeted therapy for the majority of patients with squamous and non-squamous carcinoma,' said Maurice Pérol, MD, of the Cancer Research Center of Lyon in France. Ramucirumab specifically targets VEGFR-2 and inhibits angiogenesis, and it has been shown to improve outcomes in gastric cancer as monotherapy."


Editor's note: This article describes a treatment for advanced non-small cell lung cancer (NSCLC) that combines a new targeted drug called ramucirumab with the standard chemotherapy drug docetaxel. In a clinical trial to test the treatment in volunteer patients who had already received one previous treatment, it was found that ramucirumab plus docetaxel provided better patient outcomes than docetaxel plus a placebo.

Cancer Commons's insight:

Cancer Network  |  Jun 19, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Positive Results For Vargatef in Lung Cancer Study

Positive Results For Vargatef in Lung Cancer Study | Lung Cancer Dispatch | Scoop.it

New clinical trial results suggest that adding the drug nintedanib (Vargatef) to second-line chemotherapy can improve survival for some patients with non-small cell lung cancer (NSCLC). Patients with advanced NSCLC whose cancer had progressed after first-line chemotherapy received either Vargatef and the chemotherapy drug docetaxel (Taxotere) or Taxotere alone. On the whole, Vargatef was associated with slightly longer times without worsening of the cancer (3.4 months vs 2.7 in the Taxotere-only group), but no improvement in overall survival. However, in patients with lung adenocarcinoma, a subtype of NSCLC, the addition of Vargatef improved overall survival by over 2 months (12.6 months vs 10.3 with Taxotere alone). Vargatef disrupts the formation of new blood vessels that feed growing tumors.

Cancer Commons's insight:

Clinical Oncology News  |  Oct, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Gene Variations May Predict Outcomes in Non-Small Cell Lung Cancer

Gene Variations May Predict Outcomes in Non-Small Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

Variations in two genes called CXCR-2 and PAR-1 may predict how a person with non-small cell lung cancer (NSCLC) will fare. A study of over 200 NSCLC patients found that those with certain versions of the genes were likely to experience faster disease progression and shorter survival, especially if patients had squamous cell carcinoma (SCC). Both genes are involved in tumor angiogenesis, that is, the growth of new blood vessels that enable tumors to expand. In the future, testing for these high-risk gene variants may help identify good candidates for anti-angiogenesis treatments like bevacizumab (Avastin).

Cancer Commons's insight:

Lung Cancer | Mar 30, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Nintedanib: New Oral Angiogenesis Inhibitor in Lung Cancer

"A new oral angiogenesis inhibitor for the treatment of lung cancer could be edging closer to the market: Approval application for nintedanib (Boehringer Ingelheim) has been filed in Europe and is being prepared for the United States.


"The data for nintedanib come from the phase 3 trial known as LUME-Lung-1, recently published in the Lancet Oncology."


Editor's note: We previously posted a story about the potential benefits of the drug nintedanib for some patients with non-small cell lung cancer (NSCLC).

Cancer Commons's insight:

Medscape  |  Mar 28, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Molecular Target May Lead to Cancer Drugs that Suffocate Tumors

New Molecular Target May Lead to Cancer Drugs that Suffocate Tumors | Lung Cancer Dispatch | Scoop.it

Researchers have identified a compound that may cut off tumors' oxygen supply. Because they grow so rapidly, tumors eventually outgrow the ability of the surrounding blood vessels to transport enough oxygen and nutrients to them. In response to low oxygen levels, tumors trigger the formation of new blood vessels to keep them supplied. Now, scientists have discovered a protein, HIF-1, that acts as a 'master switch' that turns on hundreds of other genes involved in forming these new blood vessels. They then identified a new compound called cyclo-CLLFVY that blocked HIF-1 in cultured cancer cells. Researchers now hope to develop cyclo-CLLFVY into a drug that can prevent tumors from getting the oxygen they need to survive.

Cancer Commons's insight:

Cancer Research UK | Jul 26, 2013

more...
Cancer Commons's curator insight, August 1, 2013 2:47 PM

Cancer Research UK | Jul 26, 2013

Cancer Commons's curator insight, August 1, 2013 2:47 PM

Cancer Research UK | Jul 26, 2013

Cancer Commons's curator insight, August 1, 2013 2:47 PM

Cancer Research UK | Jul 26, 2013